"1. The complaint is to be denied.
2. Auxiliary to no. 1 above, the Patent is to be upheld with the following
limited claims:
1. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration, wherein the formulation comprises fulvestrant in a
ricinoleate vehicle, a pharmaceutically acceptable non-aqueous
ester solvent, and a pharmaceutically acceptable alcohol, and
wherein the formulation is adapted for attaining a therapeutically significant bloodplasma fulvestrant concentration for at least
2 weeks.